IL-15 in HIV infection: Pathogenic or therapeutic potential?

European Cytokine Network

Volumn 21, Issue 3, 2010, Pages 219-221

  Mueller, Yvonne M ^a   Katsikis, Peter D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; HIV; IL 15; T cells

Indexed keywords

ADJUVANT; ANTIRETROVIRUS AGENT; INTERLEUKIN 15;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG INTERMITTENT THERAPY; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; NONHUMAN; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; VIRUS REPLICATION; ARTICLE; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALIA; SIMIAN IMMUNODEFICIENCY VIRUS;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-15;

EID: 77957335238     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2010.0198     Document Type: Review

References (35)

1. Diab A, Cohen AD, Alpdogan O, Perales MA. IL-15: targeting CD8+ T cells for immunotherapy. Cytotherapy 2005; 7: 23.
2. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329.
3. Arnoult D, Petit F, Lelievre JD, et al. Caspase-dependent and - independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ 2003; 10: 1240.
4. Chehimi J, Marshall JD, Salvucci O, et al. IL-15 enhances immune functions during HIV infection. J Immunol 1997; 158: 5978.
5. Kanai T, Thomas EK, Yasutomi Y, Letvin NL. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol 1996; 157: 3681.
6. Mueller YM, Bojczuk PM, Halstead ES, et al. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 2003; 101: 1024.
7. Mueller YM, Petrovas C, Do DH, et al. Early establishment and antigen dependence of simian immunodeficiency virus-specific CD8+ T-cell defects. J Virol 2007; 81: 10861.
8. Petrovas C, Mueller YM, Dimitriou ID, et al. HIV-specific CD8+ T cells exhibit markedly reduced levels of Bcl-2 and Bcl-xL. J Immunol 2004; 172: 4444.
9. Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995; 182: 1067.
10. Zaunders JJ, Moutouh-de Parseval L, Kitada S, et al. Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 2003; 187: 1735.
11. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83: 3719.
12. Kornfeld C, Ploquin MJ, Pandrea I, et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005; 115: 1082.
13. Eberly MD, Kader M, Hassan W, et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J Immunol 2009; 182: 1439.
14. Mueller YM, Do DH, Altork SR, et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J Immunol 2008; 180: 350.
15. Okoye A, Park H, Rohankhedkar M, et al. Profound CD4+/CCR5 + T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J Exp Med 2009; 206: 1575.
16. Amicosante M, Poccia F, Gioia C, et al. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis 2003; 188: 661.
17. Marcondes MC, Burdo TH, Sopper S, et al. Enrichment and persistence of virus-specific CTL in the brain of simian immunodeficiency virus-infected monkeys is associated with a unique cytokine environment. J Immunol 2007; 178: 5812.
18. Boulassel MR, Mercier F, Gilmore N, Routy JP. Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV- 1-infected subjects. Clin Immunol 2007; 124: 149.
19. Mueller YM, Petrovas C, Bojczuk PM, et al. Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques. J Virol 2005; 79: 4877.
20. Picker LJ, Reed-Inderbitzin EF, Hagen SI, et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 2006; 116: 1514.
21. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7: 235.
22. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18: 399.
23. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 392.
24. Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417.
25. Villinger F, Miller R, Mori K, et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 2004; 22: 3510.
26. Munger W, DeJoy SQ, Jeyaseelan Sr R, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995; 165: 289.
27. Lentsch AB, Miller FN, Edwards MJ. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 1999; 47: 243.
28. Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 2006; 28: 231.
29. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112.
30. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401.
31. Leone A, Picker LJ, Sodora DL. IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. Curr HIV Res 2009; 7: 83.
32. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361: 1548.
33. Farel CE, Chaitt DG, Hahn BK, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103: 3282.
34. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115: 1839.
35. Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 2002; 100: 2159.